We compared the gene expression pattern of thymic tumors from precursor T-cell lymphoblastic lymphoma/leukemia (pre-T LBL) that arose in transgenic mice that overexpressed SCL, LMO1 or NUP98-HOXD13 (NHD13) with that of thymocytes from normal littermates. Only two genes, Ccl8 and Mrpl38, were consistently more than fourfold overexpressed in pre-T LBL from all three genotypes analyzed, and a single gene, Prss16 was consistently underexpressed. However, we identified a number of genes, such as Cfl1, Tcra, Tcrb, Pbx3, Eif4a, Eif4b and Cox8b that were over or under-expressed in pre-T LBL that arose in specific transgenic lines. Similar to the situation seen with human pre-T LBL, the SCL/LMO1 leukemias displayed an expression profile consistent with mature, late cortical thymocytes, whereas the NHD13 leukemias displayed an expression profile more consistent with immature thymocytes. We evaluated two of the most differentially regulated genes as potential therapeutic targets. Cfl1 was specifically overexpressed in SCL-LMO1 tumors; inactivation of Cfl1 using okadaic acid resulted in suppression of leukemic cell growth. Overexpression of Ccl8 was a consistent finding in all three transgenic lines, and an antagonist for the Ccl8 receptor-induced death of leukemic cell lines, suggesting a novel therapeutic approach.
Introduction
It has been shown that gene expression profiling is a useful technique for classification, subtype discovery and prognosis in patients with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T LBL).
1,2 Many pre-T LBL patients show chromosomal aberrations that result in the generation of fusion genes and/or the aberrant expression of proto-oncogenes. In addition, gene expression profiling and quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) has been shown to detect aberrantly expressed proto-oncogenes in the absence of chromosomal abnormalities. SCL (TAL1), HOX11, LYL1, LMO1 and LMO2 are frequently overexpressed in patients with pre-T LBL.
1,2 SCL was shown to be upregulated in 49% of the cases with pre-T LBL and considered to be associated with relatively unfavorable prognosis. Additional studies have been employed to identify the important alterations in gene expression, as well as to identify mechanism(s) that lead to altered gene expression. 3, 4 One advantage of studying genetically engineered mice is that the inciting event is known, which makes classification more straightforward. To identify candidate genes that might contribute to T-cell leukemogenesis in the context of aberrant expression of known T-cell oncogenes, we compared the gene expression profile of thymic tumors from pre-T LBL that arose in transgenic mice that overexpressed SCL, LMO1 and NUP98-HOXD13 (NHD13) with that of thymocytes from normal littermates. We have proceeded to evaluate several of the candidate genes as potential therapeutic targets for treatment of pre-T LBL.
Materials and methods
Mouse models for human pre-T LBL LMO1 transgenic mice that overexpress LMO1 driven by the lck promoter were obtained from Dr Stanley Korsmeyer (Dana Farber Cancer Institute; deceased). 5 SCL transgenic mice that overexpresses SCL under control of the SIL promoter has been described previously. 6 SCL-LMO1 double transgenic mice were generated by crossing the SIL-SCL mice with lck-LMO1 mice. 6, 7 NHD13 transgenic mice that express a NUP98-HOXD13 fusion from vav regulatory elements have been described previously. 8 Thymic tumors were harvested from clinically ill transgenic mice. Normal thymi were harvested from 40 nontransgenic littermates. Both thymic tumors and normal thymi were immediately frozen on dry ice and transferred to liquid nitrogen. In some cases, single-cell suspensions of the thymic tumors were cultured in Iscove's modified Dulbecco's medium, with 15% fetal bovine serum 9 to establish pre-T LBL cell lines.
Microarray analysis
RNA was isolated from cryopreserved thymic tumors and normal thymocytes with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and purified with RNeasy MiniElute Cleanup kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The purified RNA was assessed by electrophoresis through denaturing agarose gels to verify that it was not degraded. The RNA from 40 normal thymi were pooled and used as a reference RNA. First-strand cDNA was synthesized and dye-coupled using a FairPlay Microarray labeling kit (Stratagene, La Jolla, CA, USA). The experimental cDNA probe was labeled with Cy3 and the reference cDNA probe was labeled with Cy5. Dye-coupled cDNA was purified with a Qiagen Mini Elute PCR purification kit. The Cy3-labeled experimental probe was combined with the Cy5-labeled reference probe and the mixture was hybridized to an NCI production oligonucleotide DNA microarray containing 22 272 long oligonucleotide (70 mer) features (Compugen, San Jose, CA, USA). The microarray was scanned using an Axon GenePix scanner. The fluorescence ratio was quantified for each transcript and reflected the relative abundance of the gene in the experimental mRNA sample compared with the reference mRNA. Statistical analyses, hierarchical clustering and gene ontology of the differentially regulated genes were analyzed according to the NCI mAdb web site (http://nciarray.nci.nih.gov/ ). Briefly, the signal intensity was defined as the mean pixel intensity minus median background pixel intensity. A log base 2 ratio of tumor to normal signal was calculated by dividing the tumor signal intensity by the normal thymus signal intensity. A raw gene list of those genes either fourfold upregulated or fourfold downregulated was obtained, and then curated by hand to eliminate duplicate genes. Any multiple occurrences of features were reduced to a single instance by selecting the feature with the strongest signal (Channel A þ Channel B). In some cases, the identity of anonymous (such as the Riken collection) genes could be ascertained by comparing to the most recent Genbank release.
Okadaic acid and Ccr3 antagonist treatment
Leukemic cell lines established from the thymic tumors of SCL-LMO1 and NHD13 transgenic mice were cultured in the presence of the CCR3 antagonist, SB328437 (Sigma-Aldrich, St Louis, MO, USA), at the concentration of 69 mM for 72 h or vehicle (dimethylsulfoxide) alone. In separate experiments, SCL-LMO1 or NHD13 cell lines were treated with 1 mM okadaic acid (OA; Sigma-Aldrich) or vehicle (dH 2 O) alone for 4 h. Viable cells were evaluated by Trypan blue exclusion.
Western-blot analysis
Extracts of leukemic cell lines were prepared by lysing cells in HNTG buffer supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, MO, USA) for 1 h. Whole-cell lysate (40 mg) was separated on an 8% Tris-Glycine Gel (Invitrogen) at 125 V for 90 min and then transferred to a nitrocellulose membrane. Membranes were blocked for 1 h in SuperBlock Blocking buffer (Pierce, Rockford, IL, USA) and placed in appropriate primary antibody dilution (in TBS, 5% Blotto, 2.5% Tween 20). Primary antibody (anti Cfl1, #3311, and antiphospho-Cfl1, #3312; Cell Signaling, Danvers, MA, USA) was detected using horseradish peroxidase-linked goat anti-rabbit IgG antibodies and visualized using the chemiluminescent detection system (SuperSignal; Pierce, Rockford, IL, USA).
Transfections of SCL-LMO1 pre-T LBL cell line
We transfected a NHD13 expression vector into a pre-T LBL cell line (#6812) established from SCL-LMO1 transgenic mice using DMRIE-C reagent and the manufacturer's recommended protocol (Invitrogen, Carlsbad, CA, USA). The NHD13 expression vector used EF1alpha regulatory sequences and the NHD13 cassette was identical to that reported previously. 8 
RT-PCR
RNAs were extracted with Trizol reagent, and 1.0 mg of RNA was reverse-transcribed using Superscript II reverse transcriptase with an oligo (dT) primer (Invitrogen). The first-strand cDNAs were amplified with mouse Pbx3F primers 5 0 -CAATTATAGAG CAGGCAAGGTTCACCCTG-3 0 and mouse Pbx3R primers 5 0 -GTTCAGAGGTAGTAAGTGAGCGCTCTA-3 0 in the volume of 20 ml. After a 'hot start' at 941C, 35 cycles of 941C for 1 min, 621C for 1 min, and 721C for 1 min was used, followed by a terminal 10 min extension at 721C. PCR products were analyzed by agarose gel electrophoresis.
Results

Hierarchical clustering of tumors obtained from different lines of transgenic mice
We used two-color hybridization of high-density oligonucleotide microarrays containing 22 272 features to compare the gene expression profiles of individual mouse tumors to a reference of normal thymus RNA. To produce a large supply of normal thymus reference RNA, 40 mice aged 3-6 months were killed and the thymi harvested. We assayed 12 SCL/LMO1, 10 NHD13 and four LMO1 only pre-T LBL samples, as well as two normal thymi. Hierarchical clustering of the arrays using a classical Pearson analysis revealed four major groups: SCL/LMO1 tumors, normal thymus, NHD13 tumors and a fourth group consisting primarily of LMO1 only tumors ( Figure 1 ). All tumors of the same genotype clustered together, with the exception of two NHD13 tumors (arrays ma18-40C and À43C, mouse #1149 and 1901).
Differentially expressed genes and gene ontology Table 1 shows the genes that were most highly over-or underexpressed relative to normal thymus. There were only 12 genes whose mean expression levels were more than fourfold increased when all three groups of tumors (LMO1, SCL/LMO1 and NHD13) were analyzed, and none of these were more than 7.5-fold increased. These represented a diverse group of genes including notch-signaling pathway (Dtx1), immune-system genes (Iltifb, Igh, Ccl8, Tcrb), polypeptide elongation factors (Eef2, Eef-tu and Mrpl38), Lmo1 and Ftl1. Genes with the highest fold decrease included three related fatty acid-binding proteins (Fabp4, Fabp9 and Fabp3), apoptosis pathway genes (Cox8b and Cidea) and CD83. These results suggested that there were relatively few genes consistently overexpressed in tumors arising in all three transgenic lines compared to normal thymus.
Because tumors derived from mice with the same genotypes clustered closely together, we repeated the analysis of the most differentially expressed genes using tumors from each genotype individually. Table 2 shows genes that are more than fourfold increased in the SCL-LMO1 tumors compared to normal thymus. The two the most highly overexpressed genes were ferritin light chain (Ftl1) and cofilin 1 (Cfl1). Additional overexpressed genes included a large number that encoded proteins involved in the immune response (Tcra, Tcrb, Igh, Iltifb, Ccl8 and Tcf7), cell proliferation and division (Pin1, Cdk4, Map2k4, Cdc37 and Ctnnb1), protein translation (Eef1a1, Eef-tu, Eif4a1, Eef2, Eif5a, Tceal8, Eif4b, Mrpl38 and L13) and Notch signaling (Notch1 and Dtx1). Genes with the most significantly decreased expression again included apoptotic pathway genes (Cox8b, Cox7a1, Ucp1 and Cidea), genes encoding fatty acidbinding proteins (Fabp3, -4 and -9) and CD83.
Somewhat surprisingly, there was relatively little overlap between the most highly overexpressed genes in the SCL-LMO1 set and the LMO1 only set (Table 3) . Of the 22 genes that were fourfold increased in the LMO1 tumors compared to normal thymus, only five (Igh, Dtx1, Iltifb, Ccl8 and Mrpl38) were also at least fourfold increased in the SCL-LMO1 tumors. There also was relatively little overlap between the SCL-LMO1 group and the LMO1 only group among the genes with the highest fold decrease compared to normal thymus. Prss16, Tctex1, Cidea, Dstb and Diras2 were five of the only genes that showed decreased expression in both groups. Parodoxically, several genes that were at least fourfold increased in the SCL-LMO1 set were at least fourfold decreased in the LMO1 set. These genes included Tcrb and Tcra.
The most highly overexpressed gene in the NHD13 tumors was Pbx3, which was not overexpressed in any of the other groups of tumors. Pbx3 overexpression was of interest because Pbx3 is known to bind to Hox genes. Additional genes that were at least fourfold overexpressed included Ccl8, Tfrc, Mpo, Ctse, and several genes involved in protein synthesis (Mrpl38, Eef2 and Eif3s9) ( Table 4) . Table 1 Genes most differentially expressed in T-cell tumors compared to normal thymus 
Ccl8 is important for growth of leukemic cells (Figure 2)
We focused on Ccl8 because it was overexpressed in all three series of tumors (SCL-LMO1 (5.0-fold), LMO1 (10-fold), and the NHD13 (5.4-fold) as well as OLIG2-LMO1 tumors (8.2-fold) 10 ), and therefore a candidate for a gene that was generally important for malignant transformation of thymocytes. Because Ccl8 functions through the chemokine receptor (Ccr3), we investigated whether Ccr3 signaling was important for growth of the Ccl8-expressing cell lines. Murine pre-T LBL cell lines established from SCL-LMO1 mice, OLIG2-LMO1 mice and NHD13 mice were treated with the Ccr3 antagonist SB328437. As shown in Figure 2 , SB328437 inhibits the growth of the SCL-LMO1, OLIG2-LMO1 and NHD13 cell lines, whereas growth of a non-T-cell control (murine erythroleukemic) cell line (F4-6) was unaffected. Some genes between four-and sixfold upregulated not listed owing to space limitations.
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Cfl1 phosporylation is associated with growth inhibition of SCL-LMO1 tumors ( Figure 3) Cfl1 was 10.9-fold upregulated specifically in the SCL-LMO1 tumors. Cfl1 has been shown to be phosphorylated and inactivated in peripheral T lymphocytes. Activation through an accessory receptor leads to dephosphorylation of Cfl1 by phosphatase type 2A (PP2A). 11 Dephosphorylated Cfl1 can bind to polymeric F-actin and process it to mono-or oligomeric Gactin, which can then gain access into the nucleus. In the nucleus, G-actin contributes to transcription via inhibition of DNAse I and activation of RNA polymerase II. 12, 13 OA has been shown to specifically inhibit PP2A so that Cfl1 is phosphorylated and inactivated. 14 To investigate whether overexpression of Cfl1 is important for cell growth in SCL-LMO1 tumors, we treated leukemic cell lines with OA at the concentration of 1 mM for 4 h. A murine pre-T LBL cell line (6812), which was established from an SCL-LMO1 thymic tumor, showed activated (dephosphorylated) Cfl1. OA treatment led to simultaneous suppression of cell growth and dephosphorylation of Cfl1 in the 6812 cell line. By way of comparison, a murine erythroleukemic cell line (F4-6), which expresses less Cfl1 than the 6812 cell line, was unaffected by OA treatment, either in terms of cell viability or Cfl1 dephosphorylation.
Pbx3 is a downstream target of NHD13 (Figure 4)
Pre-B-cell leukemia transcription factors (PBXs) are important cofactors for the transcriptional regulation mediated by a number of Hox proteins.
15 PBX1 was first identified in chromosomal translocations in B-lineage leukemia and is required for normal hematopoiesis. PBX2 and PBX3 were later identified as members of this highly conserved family by their strong homology to PBX1. We found that Pbx3 was 8.3-fold upregulated exclusively in the NHD13 tumors. To investigate whether Pbx3 is a downstream target of NHD13, we transfected an NHD13 expression vector into a murine pre-T LBL cell line, 6812, which was established from an SCL-LMO1 tumor that did not overexpress Pbx3. Two NHD13 pre-T LBL primary tumors, the 2975 and the 2413, expressed Pbx3 and were used as controls. 6812 cells transfected with the NHD13 expression vector showed an expression of Pbx3 comparable to the NHD13 primary thymic tumors, whereas 6812 cell transfected with the empty vector showed only low-level Pbx3 expression, supporting the hypothesis that expression of NHD13 leads to upregulation of Pbx3.
Discussion
To gain insight into the molecular events that lead to pre-T LBL, we compared the gene expression profile of murine pre-T LBL samples to that of the normal murine thymus. We chose to analyze tumors that were initiated by defined mutations (SCL and/or LMO1 overexpression or expression of a NUP98-HOXD13 fusion gene). Our experimental approach was designed to identify two groups of differentially expressed genes. The first group of genes was those that were differentially expressed in all pre-T LBL samples, irrespective of the initiating mutation; these should be genes that are universally important for the malignant transformation of thymocytes. The second group of genes we were interested in identifying were those that were differentially expressed only in a specific subgroup of pre-T LBL (i.e., only in SCL/LMO1 mice, only in NHD13 mice, etc).
Genes identified in this manner should point to genes and pathways that might not be generally important for malignant transformation of thymocytes, but that are important for genetically defined subsets. Hierarchical clustering using a classical Pearson analysis indicated that the three groups of pre-T LBL tumors (SCL/LMO1, LMO1 only and NHD13) could be distinguished from one another, as well as from normal thymus. We identified 12 genes whose mean expression levels were at least fourfold overexpressed and 30 genes that were at least fourfold underexpressed when samples from all of the different genotype groups were analyzed together. The overexpressed genes included several known to be involved in protein synthesis (Eef2, eEF-Tu and Mrpl38), Notch signaling (Dtx1) and Ccl8. Several classes of genes were commonly underexpressed in the pre-T LBL samples, including apoptotic pathway genes (Cox8b and Cidea), 16 genes involved in T-cell differentiation (Prss16, Ccl25, CD83, Spatial, Fkbp6 and Tcrd), [17] [18] [19] [20] a group of fatty acid-binding proteins (Fabp3, Fabp4 and Fabp9), 21 and Bop1 22 and Rb1cc1, 23 two genes whose overexpression is linked to decreased cell proliferation. The Fabp proteins are typically expressed in adipocytes, 21 and their underexpression in pre-T LBL relative to normal thymus may reflect a decreased proportion of adipocytes in the pre-T LBL tumor samples compared to normal thymus. Given the rapid rate at which the malignant thymocytes proliferate, it is not surprising that several of the overexpressed genes are known to be involved in new protein synthesis. Moreover, several of the genes underexpressed in pre-T LBL with respect to normal thymus were proapoptotic or associated with decreased cell proliferation. However, because we used the mean expression level to generate Table 1 , it was possible that some of the genes were identified because they were highly upregulated in one subset only. To investigate this possibility, we analyzed differential gene expression in specific genotypes. When each genotype was analyzed separately, we were surprised to find that only two genes (Ccl8 and Mrpl38) were at least fourfold overexpressed in all three genotypes, and a single gene (Prss16) was at least fourfold underexpressed in all three genotypes.
We identified a number of genes that were overexpressed in SCL/LMO1 tumors. Several of these genes were found to be overexpressed only in the SCL/LMO1 tumors. These included Ftl1, Cfl1, Tcrb, Tcra, Pin1, and a large number of genes involved in protein synthesis (Eef1a1, Eef-tu, Ef2, Eif4a1, Eif5a, Eif4b, Tceal8 and Rpl13). Of note, TCRA and TCRB were two of the most differentially upregulated genes in human leukemias that activated SCL; 1 these findings likely reflect a differentiation arrest at the late cortical stage of thymic development. 1, 24 Also, the identification of a large number of genes involved in protein synthesis, particularly Eif4a1 and Eif4b, was of interest given recent studies showing activation of the EIF4 complex through mTOR signaling. 25 In addition, overexpression of Eif5a was of interest, as this is the only eukaryotic protein known to be activated by post-translational hypusination, and hypusination inhibitors have demonstrated an antiproliferative effect on leukemic cell lines in vitro. 26 Several other genes, including Dtx1, Iltifb, Igh, were found to be overexpressed in both the SCL/LMO1 and LMO1 only tumors. Although we had predicted that the SCL/LMO1 and LMO1 only tumors would be fairly similar, the list of commonly overexpressed genes was relatively small. Moreover, Tcra and Tcrb, among the most highly overexpressed genes in the SCL/LMO1 tumors were more than fourfold underexpressed in the LMO1 only tumors; this difference may reflect an earlier stage of thymocyte differentiation arrest in the LMO1 tumors, before the expression of Tcra and Tcrb. Of note, this finding is consistent with prior observations that overexpression of a closely related gene (LMO2), blocks thymocyte differentiation at the CD4-/CD8-(DN) stage of differentiation. 27, 28 The genes most highly over-expressed in the NHD13 pre-T LBL had little overlap with those most highly overexpressed in the SCL/LMO1 and LMO1 only tumors, except for Mrpl38 and Ccl8, discussed above, and transferrin receptor (Tfrc). There were several genes over fourfold underexpressed in both the NHD13 and LMO1, but not the SCL/LMO1 tumors. These genes included Tcra, Tcrb, H2-A, Crip3, Ubd and Diras2, and, similar to the case with human pre-T LBL that overexpress HOX11, 1, 3 likely reflect differentiation arrest at an earlier stage of thymocyte differentiation, before expression of Tcra and Tcrb. 24 The overexpression of Mpo, a gene typically expressed in myeloid cells, in the NHD13 tumors may reflect a biphenotypic differentiation potential in NHD13 pre-T LBL, a possibility consistent with the finding that NHD13 mice typically develop a myelodysplastic syndrome (MDS), which often progresses to an acute myeloid lukaemia. Alternatively, the Mpo expression might be explained by the contamination of small number of myeloid leukemic cells that were seeded from the coincident MDS present in the NHD13 mice.
We were intrigued by the observation that Ccl8 was consistently overexpressed, and hypothesized that Ccl8 might be an autocrine growth factor for pre-T LBL. As Ccl8 exerts its effects through the Ccr3 receptor, we reasoned that inhibition of the Ccr3 receptor might suppress the growth of pre-T LBL cell lines. We verified that the Ccr3 receptor was expressed in pre-T LBL cell lines, and treated four pre-T LBL cell lines, derived from SCL-LMO1, OLIG2-LMO1 or NHD13 tumors with a Ccr3 antagonist (SB328437). All four of these pre-T LBL cell lines demonstrated growth inhibition, by as much as 85%, suggesting that treatment with a Ccr3 antagonist might be an effective antileukemic therapy.
Genes whose expression levels were altered specifically in SCL-LMO1 tumors represent candidates for genes important in malignant transformation of these cells. Of those candidates, Cfl1 was 10.9-fold upregulated. As Cfl1 has been shown to be an inhibitor of glucocorticoid receptor that is consistent with the relative resistance of pre-T LBL overexpressing SCL compared to pre-T LBL with other genetic alterations, 1, 29, 30 we investigated whether the upregulation of the Cfl11 is important for proliferation of leukemic cell lines derived from SCL-LMO1 mice. It has been shown that both Ras and a costimulation of TCR/CD3 and CD28 activate mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase and phosphatidylinositol 3-kinase (PI3K), which induces the dephosphorylation of cofilin1. An activation of PI3K by stimulation through CD28 also downregulates a cyclin-dependent kinase inhibitor p27 kip1 . 31 Those cascades lead to the production of cytokines such as interleukin-2 and subsequent proliferation of T lymphocytes. 31, 32 OA, an inhibitor for the serine/threonine PP2A that phosphorylates cofilin1, treatment demonstrated inhibition of leukemic cell growth, suggesting that activation of Cfl1 is important for growth of leukemic cell lines that overexpress SCL and LMO1. Similarly, Pbx3 was specifically upregulated in NHD13 pre-T LBL; transfection of T-cell lines with an NHD13 expression vector led to upregulation of Pbx3, suggesting that Pbx3 may be a direct downstream target of NHD13.
We have used gene expression profiling to identify genes and pathways that may be important for malignant transformation of T cells in general, as well as those genes and pathways that may be important for transformation of T cells that express known oncoproteins. We found relatively few genes consistently overor underexpressed in pre-T LBL compared to normal thymus, and a larger number of genes that may be important for transformation of thymocytes that express known oncoproteins. Similar to findings with human pre-T LBL, we suspect that the differences in gene expression profile seen in different genetically defined subsets of pre-T LBL may reflect different stages of thymocyte maturation arrest. We tested and confirmed several of the genes that were candidates for general or specific involvement in the malignant transformation of thymocytes, and have identified Ccr3, the Ccl8 receptor, as a novel potential target for treatment of pre-T LBL.
